CL
SRPT icon

Choreo LLC’s Sarepta Therapeutics SRPT Stock Holding History

Choreo LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,551
Closed -$679K – 1723
2024
Q3 		$679K Buy
5,551
+4,040
+267% +$558K 0.01% 753
2024
Q2 		$237K Buy
+1,511
New +$194K ﹤0.01% 1235

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Choreo LLC's SRPT Position: Q4 2024 in Review

Choreo LLC sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 5,551 shares — an estimated $679K sold.

Choreo LLC first reported a position in SRPT in Q2 2024 and held it in 2 quarters. The position peaked at $679K in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

  • Choreo LLC reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Choreo LLC sold 5,551 Sarepta Therapeutics shares in Q4 2024, an estimated $679K.
  • Choreo LLC first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 2 quarters.
  • Choreo LLC's Sarepta Therapeutics position peaked at $679K in Q3 2024.
  • 464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Choreo LLC's 13F filing for Q4 2024, filed 27 Jan 2025.